Board of Directors
Curt Bilby, PhD
President and CEO, Terapio Corporation
J. David Enloe
J. David Enloe Jr. is Head of Lonza’s Viral-Based Therapeutics business and Director of Sales – Americas for Lonza Biosciences. Lonza is a global provider of goods and services to the life-sciences industry, based in Basel, Switzerland. In 2010, Lonza purchased the company Mr. Enloe founded and was President and CEO of, Vivante GMP Solutions, Inc. Vivante and now Lonza Viral provides process development, scale-up and GMP manufacturing of viral-based biologics for clients in the US, Europe and Japan. Prior to founding Vivante, Mr. Enloe was with Introgen Therapeutics, Inc. for over 14 years, joining as that company’s first full-time employee and rising in responsibility over time to COO for several years before ultimately serving as Introgen’s President and CEO. From 1989 to 1995, he held various positions at a division of Baker Hughes, Inc., an energy services company, including Region General Manager, Southeast Asia, and he worked at Arthur Andersen LLP as an accountant prior to that time. Mr. Enloe is a Certified Public Accountant and received his B.B.A. in accounting from The University of Texas at Austin.
Jim Graham, CFA
Jim Graham joined Santé Ventures in 2009. Mr. Graham came to Santé from the Boston Office of McKinsey & Company where he was an engagement manager in the Pharmaceuticals and Medical Products practice. Prior to McKinsey, Mr. Graham was an analyst in the technology investment banking group of Deutsche Bank Alex.Brown in San Francisco. Mr. Graham received his SM and MBA degrees through the Harvard-MIT Biomedical Enterprise Program and holds a BS in Biological Sciences from Stanford University with honors.
Casey Cunningham, MD
Casey Cunningham, MD is the Chief Scientific Officer of Santé Ventures and the Chief Medical Officer of two portfolio companies, Terapio and Molecular Templates. Dr. Cunningham received his fellowship training in oncology and hematology at the Harvard Medical School, where he subsequently served on the faculty. He was also one of the founding members of the Division of Experimental Medicine at the Brigham & Women’s Hospital in Boston, where he established a basic research laboratory in Cell and Molecular Biology. Dr. Cunningham received his medical degree from the University of Texas Southwestern Medical School with a residency in Internal Medicine at the Medical College of Wisconsin. Dr. Cunningham returned to Texas in 1999 as the Associate Director of the Mary Crowley Cancer Research Center in Dallas, a position he held until 2007. The MCCRC performs early phase drug development and Dr. Cunningham was the principal investigator on numerous trials, with a particular emphasis on gene and cell-based therapies. He has over 60 publications in peer-reviewed journals and many abstracts and meeting presentations.
Prior to founding Santé Ventures, Kevin Lalande spent seven years with Austin Ventures, a prominent venture firm with $3.9 billion under management. Before joining Austin Ventures, he was a management consultant with McKinsey & Company. Previously, Mr. Lalande co-founded and sold three successful start-up companies: NetProfit, sold to a privately held advertising agency in 1996; Serus, sold to Netopia (Nasdaq: NTPA) in 1998; and TimeMarker, sold to PrimeHoldings (OTCBB: PRIM) in 2001. Mr. Lalande received an MBA with highest distinction (Baker Scholar) from the Harvard Business School and holds a BS in Electrical and Computer Engineering.